^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    PD1 inhibitor

    Related drugs:
    13h
    Camrelizumab Combined With AVD in the First-line Treatment for Patients With Advanced Classical Hodgkin's Lymphoma (clinicaltrials.gov)
    P2, N=60, Recruiting, Henan Cancer Hospital | Trial completion date: Dec 2024 --> Dec 2026 | Trial primary completion date: Jun 2024 --> Dec 2025
    Trial completion date • Trial primary completion date
    |
    AiRuiKa (camrelizumab) • epirubicin • vincristine • dacarbazine
    15h
    ZeTA: A Study to Evaluate Zanubrutinib and Tislelizumab in Progressive Lymphoma Post CAR-T (clinicaltrials.gov)
    P2, N=76, Not yet recruiting, University Health Network, Toronto | Trial primary completion date: Dec 2025 --> Apr 2026
    Trial primary completion date
    |
    Tevimbra (tislelizumab-jsgr) • Brukinsa (zanubrutinib)
    15h
    Pembrolizumab (MK-3475) Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced and/or Unresectable Biliary Tract Carcinoma (BTC) (MK-3475-966/KEYNOTE-966) (clinicaltrials.gov)
    P3, N=1069, Completed, Merck Sharp & Dohme LLC | Active, not recruiting --> Completed
    Trial completion
    |
    Keytruda (pembrolizumab) • cisplatin • gemcitabine
    15h
    BMS-986156, Ipilimumab, and Nivolumab With or Without Stereotactic Body Radiation Therapy in Treating Patients With Advanced or Metastatic Lung/Chest or Liver Cancers (clinicaltrials.gov)
    P1/2, N=51, Completed, M.D. Anderson Cancer Center | Active, not recruiting --> Completed | Trial completion date: Aug 2027 --> Apr 2025 | Trial primary completion date: Aug 2027 --> Apr 2025
    Trial completion • Trial completion date • Trial primary completion date • Tumor mutational burden
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • BMS-986156
    16h
    Efficacy and Safety of QL1706 in the Treatment of Advanced Bone and Soft Tissue Sarcoma: a Phase II Clinical Study (clinicaltrials.gov)
    P2, N=45, Not yet recruiting, Sun Yat-sen University
    New P2 trial
    |
    Qibeian (iparomlimab/tuvonralimab)
    17h
    A Phase II Study of Futibatinib and Pembrolizumab in Metastatic Microsatellite Stable Endometrial Carcinoma (clinicaltrials.gov)
    P2, N=30, Active, not recruiting, M.D. Anderson Cancer Center | Trial primary completion date: Sep 2025 --> Sep 2024
    Trial primary completion date
    |
    Keytruda (pembrolizumab) • Lytgobi (futibatinib)
    17h
    A Study to Compare Effects and Safety of CT-P51 and Keytruda in Patients With Previously Untreated Metastatic Lung Cancer (clinicaltrials.gov)
    P3, N=606, Recruiting, Celltrion
    New P3 trial
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • pemetrexed
    18h
    LEAP-010: A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (MK-7902-010) (KEYNOTE-010) (clinicaltrials.gov)
    P3, N=511, Completed, Merck Sharp & Dohme LLC | Active, not recruiting --> Completed
    Trial completion
    |
    Keytruda (pembrolizumab) • Lenvima (lenvatinib)
    18h
    Phase II Trial of Ivonescimab in Previously Treated Patients With Advanced Clear Cell Renal Cell Carcinoma (clinicaltrials.gov)
    P2, N=40, Not yet recruiting, M.D. Anderson Cancer Center
    New P2 trial
    |
    Yidafan (ivonescimab)
    19h
    EF-36/Keynote B36: A Pilot, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150 kHz) Concomitant With Pembrolizumab for First Line Treatment of Advanced or Metastatic Non-small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=15, Terminated, NovoCure GmbH | N=100 --> 15 | Trial completion date: Dec 2026 --> Jan 2025 | Recruiting --> Terminated | Trial primary completion date: Jul 2024 --> Jan 2025; Phase 2 study terminated due to insufficient enrollment and was not based on safety concerns. Novocure is enrolling a new Phase 3 study of TTFields as a first line treatment for advanced/metastatic NSCLC (NCT06216301).
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)
    |
    PD-L1 expression • ALK translocation
    |
    Keytruda (pembrolizumab)
    20h
    Toripalimab With Chemotherapy for Sinus Cancer (clinicaltrials.gov)
    P2, N=20, Not yet recruiting, Glenn J. Hanna
    New P2 trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    cisplatin • carboplatin • docetaxel • Loqtorzi (toripalimab-tpzi)
    20h
    CONTRAC: Cemiplimab in AlloSCT/SOT Recipients With CSCC (clinicaltrials.gov)
    P1/2, N=12, Completed, Dana-Farber Cancer Institute | Active, not recruiting --> Completed | Trial completion date: Jan 2026 --> Mar 2025
    Trial completion • Trial completion date
    |
    everolimus • Libtayo (cemiplimab-rwlc) • sirolimus
    22h
    Toripalimab Plus Lenvatinib and Gemcitabine-based Chemotherapy in 1L Treatment of Advanced ICC: a Phase III Study (clinicaltrials.gov)
    P3, N=480, Recruiting, Shanghai Junshi Bioscience Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    cisplatin • gemcitabine • Lenvima (lenvatinib) • Loqtorzi (toripalimab-tpzi) • oxaliplatin
    23h
    CheckMate 9ER: A Study of Nivolumab Combined With Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (clinicaltrials.gov)
    P3, N=701, Active, not recruiting, Bristol-Myers Squibb | Trial completion date: Apr 2024 --> Jan 2026
    Trial completion date
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • sunitinib • Cabometyx (cabozantinib tablet)
    23h
    Study of Cabozantinib and Nivolumab in Refractory Metastatic Microsatellite Stable (MSS) Colorectal Cancer (clinicaltrials.gov)
    P2, N=48, Active, not recruiting, University of Colorado, Denver | Trial primary completion date: Feb 2025 --> Feb 2026
    Trial primary completion date
    |
    BRAF (B-raf proto-oncogene) • MSI (Microsatellite instability)
    |
    RAS wild-type
    |
    Opdivo (nivolumab) • Cabometyx (cabozantinib tablet)
    3d
    Immunotherapy With or Without SBRT in Patients With Stage IV Non-small Cell Lung Cancer (clinicaltrials.gov)
    P3, N=5, Completed, Wake Forest University Health Sciences | Active, not recruiting --> Completed | Trial completion date: Jul 2027 --> Apr 2025 | Trial primary completion date: Jul 2027 --> Apr 2025
    Trial completion • Trial completion date • Trial primary completion date
    |
    Keytruda (pembrolizumab)
    4d
    Neoadjuvant Apatinib Combined With Sintilimab and Perioperative SOX Versus Neoadjuvant Sintilimab Combined With Perioperative SOX for Intestinal Type of Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma (clinicaltrials.gov)
    P3, N=682, Recruiting, Zuoyi Jiao | Not yet recruiting --> Recruiting
    Enrollment open
    |
    PD-L1 (Programmed death ligand 1)
    |
    Tyvyt (sintilimab) • AiTan (rivoceranib) • oxaliplatin
    4d
    A Study of AK130 in Combination With AK112 for the Treatment of Advanced Biliary Tract Cancer (clinicaltrials.gov)
    P1/2, N=135, Not yet recruiting, Akeso
    New P1/2 trial
    |
    Yidafan (ivonescimab)
    4d
    MAHOGANY: Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer (clinicaltrials.gov)
    P2/3, N=82, Completed, MacroGenics | Active, not recruiting --> Completed
    Trial completion
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression • HER-2 positive
    |
    PD-L1 IHC 22C3 pharmDx
    |
    Herceptin (trastuzumab) • 5-fluorouracil • capecitabine • oxaliplatin • Margenza (margetuximab-cmkb) • Zynyz (retifanlimab-dlwr) • tebotelimab (MGD013)
    4d
    TIP Regimen Combined With Triplizumab Neoadjuvant Therapy for Locally Advanced Penile Cancer (clinicaltrials.gov)
    P2, N=25, Recruiting, Sun Yat-sen University | Not yet recruiting --> Recruiting
    Enrollment open
    |
    cisplatin • paclitaxel • Loqtorzi (toripalimab-tpzi) • ifosfamide
    4d
    PERLA: Efficacy Comparison of Dostarlimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) (clinicaltrials.gov)
    P2, N=243, Terminated, GlaxoSmithKline | Completed --> Terminated; Trial terminated by GSK for strategic reasons, after all participants completed treatment. This decision was not based on a safety concern
    Trial termination
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    BRAF V600E • BRAF V600 • ALK mutation
    |
    PD-L1 IHC 22C3 pharmDx
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • Jemperli (dostarlimab-gxly)
    4d
    Using ctDNA to Guide Treatment Decisions for Stage III Gastric Cancer (clinicaltrials.gov)
    P3, N=416, Active, not recruiting, The First Affiliated Hospital with Nanjing Medical University
    New P3 trial • Circulating tumor DNA
    |
    Tevimbra (tislelizumab-jsgr) • oxaliplatin
    4d
    Pembrolizumab for HPV-associated Recurrent Respiratory Papilloma Patients (clinicaltrials.gov)
    P2, N=21, Active, not recruiting, Massachusetts General Hospital | Trial completion date: Jul 2024 --> Jul 2025
    Trial completion date
    |
    Keytruda (pembrolizumab)
    4d
    Rituximab and Hyaluronidase Human in Patients With Advanced Melanoma Undergoing Nivolumab and Ipilimumab Therapy (clinicaltrials.gov)
    P2, N=15, Active, not recruiting, Emory University | Trial completion date: Sep 2024 --> Jun 2026
    Trial completion date • Checkpoint inhibition
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • Rituxan Hycela (rituximab/hyaluronidase)
    4d
    NRG-BN007: Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab Plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated Glioblastoma (clinicaltrials.gov)
    P2/3, N=159, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Mar 2025 --> Mar 2026
    Trial completion date • Tumor mutational burden
    |
    PD-L1 (Programmed death ligand 1) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • MGMT (6-O-methylguanine-DNA methyltransferase)
    |
    MGMT promoter methylation • IDH1 R132
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • temozolomide • ABP 206 (nivolumab biosimilar)
    4d
    Study of ZGGS18 in Combination With ZG005 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=60, Not yet recruiting, Suzhou Zelgen Biopharmaceuticals Co.,Ltd
    New P1/2 trial
    |
    ZG005 • ZGGS18
    4d
    Cryoablation Combined With Tislelizumab and Chemotherapy as Neoadjuvant and Adjuvant Therapy in Resectable Stage II-IIIB NSCLC (clinicaltrials.gov)
    P2, N=38, Recruiting, Tianjin Medical University Cancer Institute and Hospital
    New P2 trial
    |
    cisplatin • carboplatin • Tevimbra (tislelizumab-jsgr) • albumin-bound paclitaxel
    4d
    FRAPPE: Vaccine Therapy Plus Pembrolizumab in Treating Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer (clinicaltrials.gov)
    P1/2, N=40, Suspended, Mayo Clinic | Recruiting --> Suspended
    Trial suspension
    |
    MUC16 (Mucin 16, Cell Surface Associated)
    |
    Keytruda (pembrolizumab)
    4d
    Single Agent Pembrolizumab in Subjects With Advanced Adrenocortical Carcinoma (clinicaltrials.gov)
    P2, N=39, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Feb 2025 --> Feb 2026
    Trial completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    Keytruda (pembrolizumab)
    4d
    Pathologically Complete Response to Camrelizumab and Apatinib in Advanced Cervical Cancer with PTEN, PIK3CA, MTOR, and ARID1A Mutations: A Case Report. (PubMed, Case Rep Oncol)
    Limited treatment options are available for residual locally advanced cervical cancer after concurrent radio-chemotherapy. Camrelizumab is affordable, at just 10% of the price of pembrolizumab, although it is similarly not covered by medical insurance for cervical cancer in China. The PTEN, PIK3CA, MTOR, and ARID1A gene mutations hold the potential to serve as predictive biomarkers for cervical cancer patients treated by PD-1 inhibitors.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • PTEN (Phosphatase and tensin homolog) • ARID1A (AT-rich interaction domain 1A)
    |
    PIK3CA mutation • PTEN mutation • ARID1A mutation
    |
    Keytruda (pembrolizumab) • AiRuiKa (camrelizumab) • AiTan (rivoceranib)
    4d
    Pembrolizumab versus bevacizumab plus modified FOLFOX6 in metastatic MSI-H/dMMR colorectal cancer: a multicenter retrospective study with CT evaluation. (PubMed, Front Oncol)
    Pembrolizumab monotherapy significantly improved survival over bevacizumab-based chemotherapy in metastatic MSI-H/dMMR CRC, with a manageable safety profile. These results reinforce PD-1 inhibitors as first-line therapy for this population, while highlighting tumor mutation burden (TMB) and tumor burden as critical biomarkers for personalized strategies.
    Retrospective data • Journal • Tumor mutational burden • MSi-H Biomarker • PD(L)-1 Biomarker • IO biomarker • MSI-H • dMMR
    |
    TMB (Tumor Mutational Burden) • MSI (Microsatellite instability)
    |
    MSI-H/dMMR
    |
    Keytruda (pembrolizumab) • Avastin (bevacizumab) • 5-fluorouracil • oxaliplatin • leucovorin calcium
    4d
    Systemic therapy with pemigatinib and sintilimab followed by resection for recurrent FGFR-2-positive intrahepatic cholangiocarcinoma: a case report. (PubMed, Front Oncol)
    This case highlights the efficacy of pemigatinib-based systemic therapy in achieving tumor regression and enabling curative resection in locally recurrent FGFR-2-positive ICC. The successful outcome underscores the potential of targeted therapies in managing recurrent ICC, warranting further investigation.
    Journal
    |
    FGFR2 (Fibroblast growth factor receptor 2)
    |
    FGFR2 mutation • FGFR2 fusion • FGFR mutation • FGFR fusion
    |
    Tyvyt (sintilimab) • Pemazyre (pemigatinib)
    5d
    Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer (clinicaltrials.gov)
    P1, N=32, Suspended, National Cancer Institute (NCI) | Recruiting --> Suspended
    Trial suspension
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 negative
    |
    Keytruda (pembrolizumab) • paclitaxel • Inqovi (decitabine/cedazuridine)
    5d
    RHAPSODY: PD-1 Inhibitor INCMGA00012 as Consolidation Therapy After Definitive Concurrent Chemoradiotherapy (clinicaltrials.gov)
    P2, N=110, Active, not recruiting, Asan Medical Center | Not yet recruiting --> Active, not recruiting | Trial primary completion date: Jan 2024 --> Dec 2025
    Enrollment closed • Trial primary completion date
    |
    Zynyz (retifanlimab-dlwr)
    5d
    A Prospective, Single Arm, Open Label, Phase II Clinical Study on the Efficacy and Safety of Ivonescimab (AK112) Combined With TAS-102 in the Treatment of Refractory MSS/pMMR Advanced Colorectal Cancer (clinicaltrials.gov)
    P=N/A, N=35, Enrolling by invitation, Huai'an First People's Hospital
    New trial • pMMR
    |
    Lonsurf (trifluridine/tipiracil) • Yidafan (ivonescimab)
    5d
    ONO-4538 Study in Patients With Richter's Transformation (clinicaltrials.gov)
    P2, N=14, Not yet recruiting, Ono Pharmaceutical Co. Ltd
    New P2 trial
    |
    Opdivo (nivolumab)
    5d
    A Study of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastric Cancer (clinicaltrials.gov)
    P2, N=49, Recruiting, Memorial Sloan Kettering Cancer Center | N=25 --> 49
    Enrollment change
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    Keytruda (pembrolizumab) • Herceptin (trastuzumab) • docetaxel • 5-fluorouracil • capecitabine • oxaliplatin
    5d
    A Multicenter, Single-arm Phase II Study to Evaluate the Efficacy and Safety of Fulzerasib (IBI351) in Combination With Ivonescimab (AK-112) in First-line Treatment of Advanced or Metastatic Non-small Cell Lung Cancer Patients With KRAS G12C Mutation (clinicaltrials.gov)
    P2, N=39, Not yet recruiting, Shanghai Chest Hospital
    New P2 trial
    |
    Dupert (fulzerasib) • Yidafan (ivonescimab)
    5d
    A Phase II Clinical Trial to Evaluate Safety and Efficacy of XmAb20717 in Advanced Rare Cancers (clinicaltrials.gov)
    P2, N=140, Suspended, M.D. Anderson Cancer Center | Trial completion date: Apr 2025 --> Apr 2026 | Trial primary completion date: Apr 2025 --> Apr 2026
    Trial completion date • Trial primary completion date
    |
    MSI (Microsatellite instability)
    |
    MSI-H/dMMR
    |
    vudalimab (XmAb717)
    5d
    Reversible downregulation of HLA class I in adenoid cystic carcinoma. (PubMed, J Immunother Cancer)
    Low B2M/HLA class I expression may explain why ACCs are immunologically cold and the lack of response to ICIs. Our findings suggest that the normal cell of ACC origin exists in a B2M/HLA-class I low state, and that pharmacologic manipulation with immune activators, such as STING agonists, can restore HLA/B2M in ACCs, as supported by the promising response observed in a patient with metastatic ACC. These findings indicate a potential path to urgently needed immunotherapies.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • IFNG (Interferon, gamma) • B2M (Beta-2-microglobulin) • IRF1 (Interferon Regulatory Factor 1) • NFIB (Nuclear Factor I B) • TP63 (Tumor protein 63) • GBP1 (Guanylate Binding Protein 1) • TAP1 (Transporter 1)
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • dazostinag (TAK-676)
    7d
    Efficacy and safety of concurrent programmed cell death protein 1 inhibitor and definitive radiotherapy with immunonutrition support in esophageal squamous cell cancer: a phase II multicenter clinical trial. (PubMed, Radiat Oncol)
    This research has the potential to redefine treatment for inoperable ESCC patients who cannot tolerate conventional therapies. By evaluating a less toxic regimen that combines immunotherapy, radiotherapy, and nutritional support, we aim to determine if this approach can improve both survival rates and quality of life. The synergistic effects of immunonutrition support and PD-1 inhibitor will also be explored.
    Clinical protocol • P2 data • Journal
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Tyvyt (sintilimab)
    7d
    Novel PD-1-targeted, activity-optimized IL-15 mutein SOT201 acting in cis provides antitumor activity superior to PD1-IL2v. (PubMed, J Immunother Cancer)
    SOT201 represents a promising therapeutic candidate that preferentially targets PD-1+ TILs, delivering balanced cytokine activity for reviving CD8+ Tex cells in tumors. SOT201 is currently being evaluated in the Phase I clinical study VICTORIA-01 (NCT06163391) in patients with advanced metastatic cancer.
    Journal
    |
    STK11 (Serine/threonine kinase 11) • CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • IL15 (Interleukin 15)
    |
    Keytruda (pembrolizumab)